CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 296 enrolled
Drug / intervention
OROS Methylphenidatedrug
Likely dose
OROS Methylphenidate 18 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00758160
NCT00758160Phase 4Completed
CompareCT.gov

From Immediate-release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD

Johnson & Johnson Taiwan Ltd·interventional·Posted Sep 23, 2008·Updated Apr 8, 2014

In Brief

A Phase 4 clinical trial evaluating OROS Methylphenidate for Attention Deficit Disorder With Hyperactivity. Completed, enrolled 296 participants.

Detailed Summary

The purpose of this study is to evaluate whether familial relationships and psychological status of participants or caregivers as well as Attention Deficit Hyperactivity Disorder (ADHD) symptoms of participants can be improved by switching from Immediate-release Methylphenidate (IR-MPH) to Osmotic Release Oral Delivery System Methylphenidate (OROS-MPH).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Disorder With Hyperactivity
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 23, 2008
Enrollment StartMar 1, 2008
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.8 years ago

Interventions

OROS Methylphenidatedrug

Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.